WP
TRVI icon

Woodline Partners’s Trevi Therapeutics TRVI Stock Holding History

Woodline Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.1M Buy
4,081,333
+3,080,551
+308% +$44.8M 0.24% 102
2026
Q1 		$11.9M Buy
1,000,782
+500
+0% +$5.6K 0.05% 468
2025
Q4 		$12.5M Buy
1,000,282
+900,000
+897% +$10.4M 0.05% 409
2025
Q3 		$918K Sell
100,282
-3,946,153
-98% -$29.6M ﹤0.01% 808
2025
Q2 		$22.1M Buy
4,046,435
+1,988,623
+97% +$12.4M 0.12% 258
2025
Q1 		$12.9M Sell
2,057,812
-1,154,785
-36% -$5.51M 0.08% 313
2024
Q4 		$13.2M Buy
3,212,597
+2,606,370
+430% +$8.34M 0.09% 291
2024
Q3 		$2.02M Buy
+606,227
New +$1.8M 0.02% 476

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Woodline Partners's TRVI Position: Q2 2026 in Review

Woodline Partners increased its Trevi Therapeutics (TRVI) stake by 308% in Q2 2026, buying an estimated $44.8M and bringing the position to 4,081,333 shares worth $76.1M. The position accounts for 0.24% of the portfolio, ranked #102.

Woodline Partners first reported a position in TRVI in Q3 2024 and has held it in 8 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Woodline Partners held 4,081,333 shares of Trevi Therapeutics worth $76.1M as of Q2 2026.
  • Woodline Partners bought 3,080,551 Trevi Therapeutics shares in Q2 2026, an estimated $44.8M.
  • Trevi Therapeutics made up 0.24% of Woodline Partners's portfolio in Q2 2026, its #102 holding.
  • Woodline Partners first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.